Dan Riskin Net Worth: Estimated Wealth, Sources, and How It’s Calculated

Dan Riskin's net worth is estimated at between $5 million and $20 million as of May 2026, with the most likely range sitting closer to $8 million to $15 million. This estimate applies to Dan Riskin the healthcare AI entrepreneur and surgeon, CEO of Verantos, founder of Health Fidelity, and clinical professor of surgery at Stanford, not the Canadian TV biologist of the same name. The range reflects a founder-level equity stake in an AI health tech company, a prior acquisition exit valued at over $150 million, Silicon Valley executive compensation, and the typical financial profile of a serial entrepreneur in the medical technology space.

Which Dan Riskin This Covers

There are at least two public figures named Dan Riskin who show up prominently online. The first, and the one this article focuses on, is Dan Riskin, M.D., M.B.A., an American surgeon, healthcare AI entrepreneur, and academic born October 15, 1971. He is currently CEO and Founder of Verantos, based in Menlo Park, California, and holds a position as a clinical professor of surgery at Stanford University. He previously founded Health Fidelity and served as a consultant on special projects at Apple. His profile appears on the Forbes Technology Council and has been cited in NIH/NCATS publications.

The second Dan Riskin is a Canadian evolutionary biologist and television presenter with a PhD, best known as a host connected to Animal Planet's "Monsters Inside Me" and other science programming. He is based in the Greater Toronto Area. These are two completely different people, and the financial profile below has nothing to do with the TV host. If you searched for the biologist, his career trajectory as a television personality and academic sits in an entirely different wealth bracket and would require a separate analysis.

The Net Worth Estimate and What's Behind It

Pinning an exact number on a private tech founder is genuinely difficult, and anyone claiming a precise figure for Dan Riskin is overstating what the public record actually shows. If you're comparing how similar private-founder profiles get valued, you may also want to look at ron rivlin net worth. What we can do is build a reasonable range from the available signals. The estimate of $8 million to $15 million (with $5 million to $20 million as the wider uncertainty band) is anchored mainly in three things: the Health Fidelity exit, his ongoing equity in Verantos, and his accumulated professional compensation over a career spanning medicine, Silicon Valley, and academia.

How This Estimate Was Built

Net worth estimates for private individuals like Riskin don't come from a single source. They're assembled from public clues and then stress-tested against what's plausible for someone in that industry, at that stage of career, with those specific milestones. Here's the reasoning chain used for this estimate.

1. Start with the Health Fidelity acquisition: Wikipedia's entry on Riskin states Health Fidelity was acquired by Edifecs in a deal valued in excess of $150 million. As founder and CEO, Riskin would have held a meaningful equity stake. Even after accounting for dilution from venture capital funding rounds, a founder's residual stake in a $150 million-plus deal typically translates to several million dollars in personal proceeds, often more.
2. Factor in Verantos equity: Riskin founded Verantos and remains CEO as of 2026. The company is private, so its current valuation isn't publicly disclosed, but it has received NIH NCATS SBIR Phase II funding (nearly $1.5 million in 2018) and operates in the high-growth healthcare AI sector. Founder equity in an active company like this is illiquid but still contributes to net worth on paper.
3. Add professional compensation: As a Silicon Valley CEO and Stanford clinical professor, Riskin's annual compensation from salary, consulting, and academic roles likely runs in the mid-six-figure range annually, possibly higher. His prior role as a Special Projects Consultant at Apple further signals access to premium compensation.
4. Apply standard deductions: Taxes on the Health Fidelity exit, cost of living in the Palo Alto/Menlo Park area (which is extremely high), mortgage obligations, and typical investment allocation all reduce gross proceeds. These aren't confirmed but are assumed based on standard financial modeling for Silicon Valley professionals at this career level.

Income Sources and Career Compensation Signals

Riskin's income comes from several directions at once, which is typical for someone operating at the intersection of medicine, academia, and tech entrepreneurship.

• CEO of Verantos: Executive compensation at private AI health tech companies in Silicon Valley generally ranges from $300,000 to $600,000+ in total compensation (salary plus bonus), plus equity. The actual figure for Riskin is not publicly disclosed.
• Clinical Professor of Surgery at Stanford: Academic clinical professor roles at Stanford typically carry faculty salaries in the $200,000 to $400,000 range depending on clinical activity and grant funding, though these numbers vary considerably by department and arrangement.
• Health Fidelity exit proceeds: The Edifecs acquisition valued at over $150 million is the single largest confirmed wealth event in the public record. Founder equity payout depends heavily on ownership percentage at exit and investor preference stacks, but even a 5-10% residual stake would translate to $7.5 million to $15 million before taxes.
• Apple consulting (prior): A Special Projects Consultant role at Apple suggests high-value engagements, though compensation details are not public.
• Speaking, advisory, and board roles: Founders with Riskin's profile commonly accumulate additional income through advisory board compensation, speaking fees at healthcare and AI conferences, and board memberships at related companies.

Assets and Investments

Specific real estate holdings, investment accounts, or business interests for Riskin are not part of the public record as of May 2026. No property records, SEC filings, or financial disclosures have surfaced that allow for direct verification. What can be reasonably inferred from his career profile is the following.

• Real estate: Riskin is associated with Palo Alto and Menlo Park, California — two of the most expensive real estate markets in the world. A primary residence in this area, if owned rather than rented, could represent $2 million to $5 million or more in asset value, depending on when it was purchased.
• Verantos equity: His founder stake in Verantos is likely the largest single asset on paper. Because the company is private, this is illiquid and its value is speculative until a future liquidity event (acquisition, IPO, or secondary sale).
• Post-exit investment portfolio: It would be standard practice for someone who received a multi-million-dollar exit payout to hold a diversified portfolio of equities, fixed income, or alternative investments managed through a financial advisor or private wealth manager. No specifics are available.
• Potential angel investments or startup stakes: Serial entrepreneurs in Silicon Valley frequently invest in early-stage companies. If Riskin has done this, those stakes are private and not publicly tracked.

Liabilities and What We Simply Can't Confirm

Net worth is assets minus liabilities, and the liability side of Riskin's balance sheet is almost entirely opaque. Here's what the honest version of this analysis has to acknowledge.

• No public financial disclosures: Riskin is not a publicly traded company executive required to file with the SEC, and he holds no elected public office that would trigger mandatory financial disclosure. His personal finances are entirely private.
• Verantos funding structure: If Verantos raised significant venture capital, investor preference structures could reduce or subordinate Riskin's personal payout in a future exit. This is a standard risk for startup founders.
• Tax exposure from the Health Fidelity exit: A $150 million-plus acquisition generates significant capital gains tax obligations. California state taxes on top of federal rates could have consumed 35-40% of gross proceeds.
• Mortgage and cost of living: Bay Area housing costs and cost of living are among the highest in the country. Ongoing obligations here are assumed but not confirmed.
• Health Fidelity dilution: The exact percentage of Health Fidelity that Riskin owned at exit is not public. If the company raised substantial VC funding across multiple rounds, founder dilution could be significant, pushing personal proceeds lower than a top-line valuation might suggest.

Why Estimates Vary and How to Track Updates

Net worth figures for private individuals like Riskin vary across websites because every site is making different assumptions with the same limited public data. Some sites inflate numbers by applying optimistic equity valuations without accounting for dilution or taxes. Others use outdated salary benchmarks or conflate gross acquisition value with personal payout. There's no authoritative source that publishes Riskin's personal financial statement, so every number you see (including this one) is an informed estimate, not a confirmed fact.

The most reliable signals to watch for future updates are: any announcement of a Verantos acquisition or funding round (which would give a clearer company valuation and potential liquidity event), any SEC filings if Verantos ever pursues a public offering, real estate transaction records in Santa Clara or San Mateo counties (California property records are public), or major news coverage of new business ventures. Congressional testimony records and NIH grant databases are also useful for tracking Riskin's ongoing professional activity, since both have documented his work in the past.

If you want to track this figure over time, check Crunchbase for Verantos funding activity, monitor NIH Reporter for new grant awards to Verantos, and watch healthcare AI trade press for any acquisition or partnership news involving the company. Those are the most realistic paths to new information that would move this estimate meaningfully in either direction.

The bottom line is that Dan Riskin (the Verantos CEO) is almost certainly a high-net-worth individual by conventional standards, likely in the single-digit to low double-digit millions range, with the Health Fidelity exit as the cornerstone event that established that status. Some readers also compare related public-figure profiles, including Stuart Rabinowitz net worth estimates, to understand how compensation and ownership can translate into overall wealth. Everything else is additive and still accumulating. Until Verantos reaches a liquidity event or Riskin discloses finances through a public role, the precise number will remain an estimate based on the strongest available public clues.